Rodman & Renshaw Initiates Coverage On Quantum BioPharma with Buy Rating, Announces Price Target of $8
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiationPrice Target
Rodman & Renshaw analyst Michael King initiates coverage on Quantum BioPharma (NASDAQ:QNTM) with a Buy rating and announces Price Target of $8.
Rodman & Renshaw analyst Michael King initiates coverage on Quantum BioPharma (NASDAQ:QNTM) with a Buy rating and announces Price Target of $8.